The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Regulatory News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: -0.01 (-5.41%)
Spread: 0.01 (5.882%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Convertible Loan Agreement

20 Apr 2017 07:00

RNS Number : 7948C
Levrett PLC
20 April 2017
 

 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, TO UNITED STATES NEWS WIRE SERVICES OR IN OR INTO, AUSTRALIA, CANADA, JAPAN, THE UNITED STATES OF AMERICA OR SOUTH AFRICA OR ANY JURISDICTION WHERE IT IS UNLAWFUL TO DISTRIBUTE THIS ANNOUNCEMENT.

 

 

For Immediate Release 20 April 2017

Levrett Plc

("Levrett" or "the Company")

 

Convertible Loan Agreement

 

Levrett, a Company formed to acquire a target company with realisable or developed commercial technologies in the pharmaceutical and biotechnology sector, announces that it has entered into a Convertible Loan Agreement for £200,000 ("Loan") with a private investor.

 

The Loan is for a fixed term of 12 months and carries interest at 9% per annum, which the Lender can elect to convert. The Loan is convertible into new Ordinary Shares in the Company at a price of 4 pence per share ("Conversion"), and following Conversion the Lender will be granted a one-for-one warrant to subscribe for new ordinary shares at 4 pence per share, exercisable for a period of three years from Conversion. Under the terms of the Loan, the Lender will advance the total sum to the Company within three business days.

 

The proceeds from the Loan are to be used for general working capital and to support Nuformix Limited in the short-term pending completion of the potential reverse takeover as announced by the Company on 16 September 2016. The acquisition remains conditional, inter alia, on consent from the UK Listing Authority for the readmission of the combined entity to the Standard List.

 

This announcement contains inside information for the purposes of Article 7 of Regulation (EU) No 596/2014.

 

Enquiries:

Levrett Plc

Pascal Hughes, CEO

 

+44 (0) 20 7183 4342

Whitman Howard Limited (Broker and Corporate Advisor)

Niall Baird / Nick Lovering

 

+44 (0) 20 7659 1234

Gable Communications Limited (Financial PR)

John Bick

+44 (0) 20 7193 7463

+44 (0) 7872 061007

e: levrett@gablecommunications.com

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IODGMGMDMLVGNZZ
Date   Source Headline
19th Mar 20242:39 pmRNSResult of AGM
1st Mar 20247:00 amRNSSubscription to raise £150,000
15th Jan 202411:30 amRNSPosting of Annual Report and Notice of AGM
3rd Jan 20247:00 amRNSResults for the period ended 30 September 2023
18th Dec 20237:00 amRNSNXP001 Update
23rd Oct 20237:00 amRNSNotice of Allowance of NXP002 Patent in Japan
18th Sep 20237:00 amRNSNXP001 Update
24th Aug 20231:22 pmRNSResult of Annual General Meeting
31st Jul 20232:00 pmRNSNotice of AGM
26th Jul 20232:55 pmRNSHolding(s) in Company
2nd Jun 20237:00 amRNSInvestor Online Q&A
25th May 20237:00 amRNSChange of Auditor
22nd May 20237:00 amRNSUnaudited Interim Report
18th May 20237:00 amRNSNXP002 Inflammation and Duration of Action Update
26th Apr 202310:55 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSubscription to raise £70,000 & issue of Warrants
27th Mar 20237:00 amRNSNXP002 Update
13th Mar 20237:00 amRNSChange of Accounting Reference Date
15th Feb 20237:00 amRNSNXP002 Update
3rd Jan 20231:37 pmRNSHolding(s) in Company
20th Dec 20221:02 pmEQSNuformix hoping to 'initiate discussions with major pharma' in 2023
20th Dec 20227:00 amRNSNXP004 Update
13th Dec 20227:00 amRNSHalf-year Report
5th Dec 20227:00 amRNSResignation of Auditor
16th Nov 20228:50 amRNSHolding(s) in Company
4th Nov 20227:00 amRNSInvestor Webinar
23rd Sep 20227:00 amRNSNXP002 Update
23rd Sep 20227:00 amRNSNXP002 Update
25th Aug 20222:39 pmRNSResult of AGM
19th Aug 20228:57 amRNSHolding(s) in Company
10th Aug 20227:00 amRNSNXP002 Completion of Tolerability Studies
1st Aug 202212:13 pmRNSPosting of Annual Report and Notice of AGM
28th Jul 20227:01 amRNSBoard Changes
28th Jul 20227:00 amRNSAnnual Results for the year ended 31 March 2022
5th Jul 20227:00 amRNSNXP002 data to be presented at 2022 ERS Congress
29th Jun 20227:00 amRNSNXP004 Update
27th Jun 20227:00 amRNSNXP002 Update
20th Jun 20227:00 amRNSHolding(s) in Company
31st May 20227:00 amRNSDirectorate Change
30th May 20227:00 amRNSCorporate Update
12th Apr 20227:00 amRNSSecond tranche of Lanstead subscription shares
11th Apr 20223:54 pmRNSHolding(s) in Company
8th Apr 202211:21 amRNSHolding(s) in Company
7th Apr 20223:44 pmRNSHolding(s) in Company
5th Apr 20226:07 pmRNSHolding(s) in Company
28th Mar 20227:00 amRNSNXP004 Patent
2nd Mar 20227:00 amRNSAppointment of Dr Dan Gooding as Consultant
1st Mar 20227:00 amRNSChange of Auditor
14th Feb 20224:37 pmRNSHolding(s) in Company
8th Feb 20227:00 amRNSOxilio NXP-001 formulation development contract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.